Fda epinephrine extended dating

The U.S. Food and Drug Administration (FDA) recently announced an extended dating period for certain epinephrine auto-injectors. This is good news for consumers who rely on these devices to treat severe allergic reactions, known as anaphylaxis. Epinephrine is the first-line treatment for anaphylaxis and is a life-saving medication that must be readily available and reliable.

The extended dating period applies to Mylans EpiPen and EpiPen Jr., Auvi-Q, and Adrenaclick products. The FDA has determined that these products can remain on the market with an expiration date that is up to four months beyond the labeled expiration date. This is based on data from studies that showed the epinephrine auto-injectors remain stable during this period of time. This is in addition to the original expiration date on the product label.

Having medications with expiration dates that are accurate and reliable is essential for the safe and effective use of these products. This extended dating period gives consumers more assurance that their epinephrine auto-injectors are safe to use when needed to treat a severe allergic reaction. It also allows consumers to have access to medications that may be otherwise hard to obtain due to supply shortages or other reasons.

This extended dating period from the FDA should provide peace of mind for those who rely on epinephrine auto-injectors to treat anaphylaxis. Consumers should still follow the labeled expiration date provided on the product label and check with their healthcare provider or pharmacist if they have any questions or concerns about the products expiration date.